GSK, Hansoh's cancer drug meets main goal of bone cancer trial

GSK•2026-07-28

Experimental cancer drug meets main goal in late-stage bone cancer trial

GSK on Tuesday said partner Hansoh Pharmaceutical's experimental drug Ris-Rez met its main goal of keeping an aggressive bone cancer from worsening in a late-stage trial, just weeks after it succeeded in another advanced study.

GSK, Hansoh's cancer drug meets main goal of bone cancer trial

Experimental cancer drug meets main goal in late-stage bone cancer trial

Related News

DCX DexTrader targets on-chain yield-bearing collateralized derivatives data services segment

XPLR Infrastructure Q2 FY26 net income falls 51.9% to $38 million; revenue rises 6.1% to $363 million

Huntington Bancshares Inc <HBAN.O>: Truist Securities raises target price to $20 from $19

Federal Signal declares quarterly dividend of $0.15 per share

DTE Energy Q2 net income rises; maintains 2026 operating EPS guidance